Renal Cell Carcinoma
Jun 16, 2026
Ultomiris Receives US Priority Review for Adult IgA Nephropathy Treatment; FDA Approves WELIREG Plus KEYTRUDA or KEYTRUDA QLEX for Adjuvant Treatment of Select ccRCC Patients; Jazz Pharmaceuticals Highlights Phase 3 LAGOON Trial Update for Zepzelca® in Second-Line SCLC; Novartis’ delpacibart braxlosiran (del-brax) Achieves Primary Biomarker Endpoint in Phase I/II FSHD Study; Takeda’s Zasocitinib Tops Deucravacitinib in Phase 3 Psoriasis Trial, Setting a New Benchmark for Oral Therapies; IMAAVY Demonstrates Clinically Meaningful and Sustained Hemoglobin Responses in Pivotal wAIHA Study
Ultomiris Secures Priority Review Status in the US for Adult IgA Nephropathy Alexion, AstraZeneca Rare Disease announced that the FDA has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) for Ultomiris as a potential treatment for adults with Immunoglobulin A Nephropat...
Read More...
Mar 03, 2026
Merck’s WELIREG Advances with FDA Priority Review in Early RCC Supported by Compelling DFS Evidence; Roche’s Fenebrutinib Delivers Another Phase III Victory; Positive CHMP Opinion Paves Way for Novartis’ Remibrutinib in CSU Treatment; Pfizer’s BRAFTOVI Regimen Gains FDA’s Full Nod for Initial Treatment of Metastatic Colorectal Cancer; VYVGART Achieves Positive Results in Phase 3 ADAPT OCULUS Trial
Merck’s WELIREG Secures Priority FDA Review for Adjuvant Treatment in Early RCC Driven by Pivotal DFS Improvement Merck announced landmark results from its Phase 3 LITESPARK-022 trial, which evaluated the combination of KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) as an adjuvant treatment for patients with ...
Read More...
Jan 30, 2024
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors
Merck’s KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Cancer (RCC) at an Increased Risk of Recurrence Following Nephrectomy Merck, also known as MSD beyond the United States and Canada, has revealed findings from the Phase III KEYNOTE-564 trial, which a...
Read More...
Jan 23, 2024
BMS, and Exelixis’s Opdivo + CABOMETYX in First-Line Advanced Renal Cell Carcinoma; AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma; AstraZeneca’s Voydeya Receives First-ever Regulatory Approval; EMA Grants ODD to GC Biopharma’s Sanfilippo Syndrome (Type A) Treatment; FDA Approves NRx Pharma’s IND Application of NRX-101; FDA Fast Track Designation to Kyverna’s KYV-101
Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...
Read More...
Aug 01, 2023
FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa
FDA Expands GSK’s Jemperli Approval for Endometrial Cancer GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with mismatch repair deficient...
Read More...
Aug 02, 2022
Bristol-Myers Squibb’s Opdivo & Yervoy Combo Trial; Sarepta’s Gene Therapy SRP-9001 for DMD; Ionis’s End-Stage Renal Disease Drugs; FDA Approves Arcutis’s Zoryve Cream; Gilead’s Biktarvy for HIV and Hepatitis B; FDA to Review Biogen’s ALS Therapy Tofersen
Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...
Read More...
Feb 25, 2022
ASCO GU 2022: Renal Cell Carcinoma Highlights
Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRC...
Read More...
Feb 01, 2022
Immunocore’s Kimmtrak; Samsung Acquires Biogen’s Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor
Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...
Read More...
Apr 21, 2020
COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market
The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...
Read More...
Feb 21, 2019
Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M
Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible fac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
